TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02505984

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Study participants will be randomized to a placebo or drug group.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study participants will be randomized to a placebo or drug group.
Study: NCT02333227

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Xylitol gum
Description: This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
Study: NCT04108507

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: posterior branch block of spinal nerve
Description: posterior branch block of spinal nerve during Percutaneous kyphoplasty(PKP) operation
Study: NCT01042262

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% Oxygen at a flow of 2 L/min

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No oxygen flow
Study: NCT01620125

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Lactobacillus reuteri DSM 17938
Description: Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
Study: NCT02279511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADENOSINE TRIPHOSPHATE
Description: Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADENOSINE TRIPHOSPHATE
Description: Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Infusion of 500 mL of saline solution. (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Infusion of 500 mL of saline solution. (IV)
Study: NCT01882361

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: injectable naltrexone
Description: Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
Study: NCT01254305

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paroxetine, Sertraline, Citalopram or Fluoxetine.
Description: Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
Study: NCT01882361

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo comparator
Description: this placebo has no specific pharmacological activity
Study: NCT00609960

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: midazolam
Description: midazolam
Study: NCT01188135

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice messaging or Interactive voice messaging + psycho ed materials
Description: Interactive voice telephone messages reminder participants to continue to take their antidepressive medications

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interactive voice messaging or Interactive voice messaging + psycho ed materials
Description: Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
Study: NCT01254305

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules, oral administration, once daily dosing
Study: NCT00433576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resveratrol
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT03236311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR407899
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: Capsule Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Adenosine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adenosine
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regadenoson
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regadenoson
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 13N-ammonia
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 13N-ammonia
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 82Rubidium
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 82Rubidium
Description: Pharmaceutical form: Solution for injection Route of administration: Intravenous
Study: NCT01723397

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nasaleze Spray
Description: Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo spray
Description: Subjects are treated with placebo nasal spray then challenged with allergen

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allergen
Description: Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Allergen
Description: Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
Study: NCT01416129

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care socket
Description: Amputees' preferred socket.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthetic brimless socket
Description: Study socket
Study: NCT04074486

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP-O
Description: BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP-O
Description: BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.

Intervention type: DEVICE
Intervention: BrainScope Ahead 300iP-O
Description: BrainScope study battery consists of four components: recording of brain electrical activity (EEG); three neurocognitive performance tests; an electronic Near Point Convergence measurement assessment and clinical symptom assessments.

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT5
Description: Sports Concussion Assessment Tool 5

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT5
Description: Sports Concussion Assessment Tool 5

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT5
Description: Sports Concussion Assessment Tool 5

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Point Convergence
Description: Manual ocular function measurement conducted only if electronic version on device fails

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Point Convergence
Description: Manual ocular function measurement conducted only if electronic version on device fails

Intervention type: DIAGNOSTIC_TEST
Intervention: Near Point Convergence
Description: Manual ocular function measurement conducted only if electronic version on device fails
Study: NCT04550273

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic treadmill exercise
Description: The study group (n=20) received three sessions of aerobic exercise per week for 3 months. Every session was done on an electronic treadmill with no inclination started with 5 minutes warm-up then 30 minutes of moderate-intensity aerobic training with 60-75% of target heart rate then followed or ended by 5 minutes cool down.
Study: NCT01639183

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotating-oscillating Power Toothbrush
Description: A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
Study: NCT03280212

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 500 MG
Description: Tranexamic Acid 500mg oral tablets.
Study: NCT03550690

Intervention type: DEVICE
Intervention: Large Volume Paracentesis
Description: Insertion of a plastic tube into the abdomen and draining off ascitic fluid under local anaesthetic, removing the drain afterwards

Intervention type: DEVICE
Intervention: Rocket Indwelling Pleural Catheter
Description: A small plastic tube under the skin which is left in place so that the fluid can be drained if it builds up again
Study: NCT02341612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single exposure at 5°C in CWI
Description: The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: single exposure at 15°C in CWI
Description: The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: multiple exposures at 10°C in CWI
Description: The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: whole body cryotherapy (WBC)
Description: The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive recovery
Description: The control group was exposed to treatment after the EIMD protocol.
Study: NCT01929070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007
Study: NCT02079194

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P2Y12 antagonist monotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin plus P2Y12 antagonist
Study: NCT00059306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin
Description: Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Target of Blood Pressure
Description: Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure-either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: an inactive substance
Study: NCT01929070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarco and Crestor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarco and Crestor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarco and Crestor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omarco and Crestor
Study: NCT00807664

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biatain Ag
Description: Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biatain
Description: A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
Study: NCT04519944

Intervention type: DRUG
Intervention: Edoxaban
Description: This is an observational, prospective study; no treatment will be administered.
Study: NCT01372345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIPRO®XR
Description: Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
Study: NCT01299025

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training using Nintendo Wii Fit
Description: Training 2 times per week, 30 minutes, for 6 weeks.
Study: NCT01624194

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin nasal spray
Description: 24IU BID (3 x 0.1 mL \[4IU\] sprays per nostril twice daily for 4-weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
Study: NCT03234114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Description: Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple antithrombotic therapy
Description: Including warfarin with targeted INR 2.0-3.0 (Shanghai Xinyi pharma co., LTD, China), aspirin 100 mg q.d. (Bayer, Germany) and clopidogrel 75 mg q.d. (Sanofi, France)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antithrombotc therapy-1
Description: Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus clopidogrel 75 mg q.d. (Sanofi, France)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dual antithrombotc therapy-2
Description: Including dabigatran 110 mg b.i.d. (Boehringer Ingelheim, Germany) plus ticagrelor 90 mg b.i.d. (AstraZeneca, Britain)
Study: NCT00836940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Study: NCT02731534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Z-213
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saccharated Ferric Oxide
Description: The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
Study: NCT02900443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azathioprine
Study: NCT00316186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: topotecan
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
Study: NCT03084471

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab)
Description: A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI4736 (Durvalumab) + Tremelimumab
Description: Durvalumab: A human mAb of IgG 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on IC.~Tremelimumab: A human Ig G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation \[CD\]152) with CD80 and CD86 and increase release of cytokines (interleukin \[IL\]-2 and interferon \[IFN\]-γ) from human T cells, peripheral blood mononuclear cells and whole blood.
Study: NCT01123694

Intervention type: OTHER
Intervention: Survey Study
Description: Survey regarding quality of life
Study: NCT01459185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
Study: NCT01498120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine
Description: Optimal dose after titration period~0.5 mg/24 h (2.5 cm\^2)- 1 mg/24 h (5 cm\^2)- 2 mg/24 h (10 cm\^2)- 3 mg/24 h (15 cm\^2)~1 patch /day
Study: NCT04032782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM15136
Description: 10 mg/mL as protein in prefilled syringes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of HM15136
Description: Placebo in prefilled syringes
Study: NCT01341730

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 20mg
Description: 20 mg QD for 3 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg + Pioglitazone 30 mg
Description: atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
Study: NCT00836940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRC 8200
Description: Capsules, 25 to 100mg, once/ twice a day, 12 weeks
Study: NCT03379467

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: A text message sent as a reminder for immunization on the registered phone number

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interactive Reminder
Description: A text message sent as a reminder for immunization on the registered phone number which requires the receiver to respond back
Study: NCT02491905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02130856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neonatal kit
Description: Contents of the neonatal kit:~1. Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.~2. 4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.~3. Sunflower oil emollient (50 mL)~4. ThermoSpot~5. Mylar infant sleeve~6. Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.~7. Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker.
Study: NCT02601560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.
Study: NCT03881774

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: collecting cord blood for CAR-T cells culture; three days later, FC regimen (fludarabine 30mg/m2/d x 3, cyclophosphamide 600-800mg/m2/d x 2) another two days later, transfusing CAR-T cell with a dose of 0.5-3x106/kg
Study: NCT01027949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Treprostinil
Description: Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
Study: NCT02601560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI6012
Description: Participants received a single IV (24, 80, 240, and 800 mg) and SC (80 and 600 mg) MEDI6012 doses on Day 1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo SC
Description: Participants received a single SC dose of placebo matched to MEDI6012 on Day 1 of the study.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo IV
Description: Participants received a single IV dose of placebo matched to MEDI6012 on Day 1 of the study.
Study: NCT00872092

Intervention type: OTHER
Intervention: Stable-isotope labeled lactose ureide breath test
Description: 2 g 13C-labeled lactose ureide orally